Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
Ensysce Biosciences Reports First Quarter 2025 Financial Results
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.